featured
Rucaparib vs Chemotherapy for Relapsed, BRCA1- or BRCA2-Mutated Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Lancet Oncol 2022 Mar 14;[EPub Ahead of Print], R Kristeleit, A Lisyanskaya, A Fedenko, M Dvorkin, AC de Melo, Y Shparyk, I Rakhmatullina, I Bondarenko, N Colombo, V Svintsitskiy, L Biela, M Nechaeva, D Lorusso, G Scambia, D Cibula, R Póka, A Oaknin, T Safra, B Mackowiak-Matejczyk, L Ma, D Thomas, KK Lin, K McLachlan, S Goble, AM OzaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.